BRAF and thyroid gland carcinoma: However, it has been shown that there is a very low concordance in BRAF, KRAS, NRAS and TERT promoter mutations between primary or metastatic thyroid tissues and plasma ctDNAs in early stage thyroid cancer patients [165].